|Bid||3.1800 x 20000|
|Ask||3.2800 x 20000|
|Day's range||3.2000 - 3.2000|
|52-week range||0.8250 - 7.8000|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||2.04|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
IVERIC bio, Inc. announced the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer.
U.S.-based Iveric bio Inc delayed enrolment in a trial of its eye disease drug on Wednesday, two days after Provention Bio paused a study of its diabetes drug but allowed trial patients to complete their course. The FDA said the outbreak may impact clinical trials of medical products including drugs and devices, as travel limitations and other considerations cause protocol deviations. "Trials that are fully recruited and those involving the critically ill seem likely to go on without too much disruption," UBS analyst Laura Sutcliffe said in a client note.
IVERIC bio announced that due to the threat of COVID-19, the Company decided to delay enrollment in the second pivotal clinical trial for Zimura®.
IVERIC bio granted a newly hired, non-executive employee a non-statutory stock option to purchase 18,500 shares of the Company’s common stock.
IVERIC bio, Inc. announced financial and operating results for the fourth quarter and full year ended December 31, 2019 and provided a business update
IVERIC bio announced that Kourous A. Rezaei, M.D., CMO, will present at the Cowen and Company 40th Annual Health Care Conference.
IVERIC bio today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020.
On a per-share basis, the New York-based company said it had a loss of 30 cents. The company's shares closed at $1.44. A year ago, they were trading at $2.63. _____ This story was generated by Automated ...